Skip to main content

Table 2 Results of the discrete choice experiment

From: A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)

General model

All participants (n = 28)

Patient Association (n = 4)

Physicians (n = 6)

Health economics (n = 7)

Hospital pharmacy (n = 5)

Health Authorities (n = 6)

Beta (coefficient)

Standard error

Z-value

p. value

Odds ratio

Rel. Imp (%)

Rel. Imp (%)

Rel. Imp (%)

Rel. Imp (%)

Rel. Imp

Rel. Imp (%)

HRQoL

− 1.011

0.069

− 14.742

 < 0.001

0.364

23.53

14.27

20.55

25.11

22.35

21.83

Efficacy

− 0.614

0.067

− 9.175

 < 0.001

0.541

14.64

13.23

15.05

8.86

17.70

10.73

Availability of treatment alternatives

− 0.552

0.065

− 8.466

 < 0.001

0.576

13.51

11.00

9.92

6.00

16.43

19.39

Disease severity

0.514

0.065

7.907

 < 0.001

1.672

12.62

13.93

11.62

14.82

8.89

5.27

Avoided costs

− 0.452

0.064

− 7.020

 < 0.001

0.636

11.21

11.55

10.45

13.06

9.27

6.90

Age of target population

− 0.499

0.103

− 4.854

 < 0.001

0.607

7.75

6.55

8.20

2.15

8.22

10.16

Safety (seriousness of AE)

− 0.303

0.103

− 2.956

0.003

0.738

4.72

8.70

5.49

4.15

1.50

1.10

Quality of evidence

− 0.151

0.063

− 2.392

0.017

0.860

3.82

3.91

7.21

2.44

4.50

1.05

Target population

− 0.125

0.064

− 1.952

0.051*

0.883

3.12

2.62

0.38

2.13

3.61

7.26

Economic burden of the disease

0.103

0.065

1.568

0.117

1.108

2.50

3.15

3.78

2.97

2.43

2.78

Cost of treatment

0.072

0.066

1.086

0.278

1.074

1.73

2.34

2.57

4.72

0.79

4.88

Cost-effectiveness

− 0.054

0.103

− 0.518

0.604

0.948

0.83

7.57

2.83

9.46

2.04

6.15

Safety (AE frequency)

− 0.002

0.103

− 0.017

0.986

0.998

0.03

1.19

1.73

4.12

2.25

2.52

  1. *p = 0.042 (< 0.05) in the reduced model. In bold, relevant criteria for decision-making. AE: adverse events; HRQoL: health-related quality of life; Rel. Imp.: relative importance